Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon-alpha2a
- Development stage
- Unknown
- Lead developer
- University Hospital Tuebingen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Interferon-alpha2a is a recombinant human biologic (protein therapeutic) that functions as a cytokine with potent immunomodulatory and anti-inflammatory properties. It is being investigated by University Hospital Tuebingen for the treatment of Behcet's disease, specifically targeting severe ocular manifestations such as sight-threatening posterior uveitis and retinal vasculitis. The drug works by binding to the Type I interferon receptor complex, thereby modulating immune responses and suppressing inflammatory pathways. In clinical studies, including the Phase III INCYTOB trial, interferon-alpha2a demonstrated high response rates and the ability to induce complete remission of ocular vasculitis, while also showing efficacy for extraocular symptoms like genital ulcerations and arthritis.
- Brand names
- Roferon-A
- Other names
- rhIFN-alpha2arhIFN-alpha-2arhIFN-alpha 2arecombinant human interferon-alpha2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on interferon-alpha2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon-alpha2a.